Peripheral arterial disease (PAD) is a clinical manifestation of atherosclerotic disease, typically affecting the abdominal aorta, iliac arteries, and lower limbs.1 This condition is associated with a higher risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE), and is a strong predictor of both all-cause and cardiovascular mortalities.2 Additionally, hospitalizations due to PAD have led to a substantial economic burden on health care systems.3 In addition to their glucose-lowering effects, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with weight loss and have multiple favorable metabolic and anti-inflammatory effects.4 Due to their cardio- and nephro-protective properties, GLP-1RAs are recommended as first-line antidiabetic therapies for patients at high cardiovascular risk.5 Moreover, GLP-1RAs may improve arterial stiffness and provide systemic microcirculatory benefits in the peripheral vascular system

This differs from GLP-1 medications, where appetite suppression reverses within days of stopping
This trial enrolls thousands of participants with established cardiovascular disease or high cardiovascular risk and follows them for several years
Some studies show that caloric restriction can improve sleep, but a recent multi-study review found that sleep does not reliably improve from weight loss alone
Conclusion The combination of Berberine and L-Carnitine is an intriguing option for those focused on glucose support and metabolic energy
Chronic exposure data in any species is insufficient to draw conclusions about carcinogenicity, organ toxicity, or endocrine disruption from prolonged BPC-157 administration